Delbue Serena, Comar Manola, Ferrante Pasquale
Department of Biomedical, Surgical & Dental Sciences, University of Milano, Milano, Italy.
Department of Medical Sciences, University of Trieste, Trieste, Italy.
Immunotherapy. 2017 Jan;9(2):157-171. doi: 10.2217/imt-2016-0113. Epub 2016 Dec 22.
Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.
那他珠单抗是一种单克隆抗体，靶向白细胞表面的极晚期活化抗原4的α4链和α4β7整合素，用作复发缓解型多发性硬化症的单一疗法。它能显著降低复发率和残疾累积，但使用它会伴随一种非常严重的不良事件，即进行性多灶性白质脑病的发生，这是一种由人类多瘤病毒JC裂解复制引起的致命性中枢神经系统脱髓鞘疾病。本综述的主要重点是描述那他珠单抗的最新见解、其在临床实践中的当前应用、接受那他珠单抗治疗患者的管理以及与进行性多灶性白质脑病发生相关的风险分层。
